PanGenomic Health Updates on Cease Trade Order and Financial Filings

PanGenomic Health, Inc. Class A ( (TSE:NARA) ) has shared an update.

PanGenomic Health Inc. has provided an update on its management cease trade order (MCTO) issued by the British Columbia Securities Commission due to a delay in filing its audited annual financial statements for 2024. The delay was attributed to the company’s inability to pay its auditors on time, but financing has now been arranged to settle these payments. The MCTO restricts the CEO and CFO from trading company securities until the required filings are made, but does not affect shareholder trading. The company expects to complete the filings by June 30, 2025, and will continue to issue bi-weekly updates until the MCTO is revoked.

Spark’s Take on TSE:NARA Stock

According to Spark, TipRanks’ AI Analyst, TSE:NARA is a Underperform.

The overall stock score is driven by severe financial instability, with no revenue generation and increasing net losses. Technical analysis provides a mixed picture, suggesting potential short-term recovery but still reflecting overall negative momentum. The negative P/E ratio and lack of dividend yield further decrease the stock’s attractiveness.

To see Spark’s full report on TSE:NARA stock, click here.

More about PanGenomic Health, Inc. Class A

PanGenomic Health is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments. The company’s initial focus is to support mental health, and it operates as a British Columbia benefit company with a mission to promote and improve health and wellness through technology that identifies plant-based solutions tailored to individual health profiles.

Average Trading Volume: 17,475

Technical Sentiment Signal: Sell

Current Market Cap: C$1.18M

For an in-depth examination of NARA stock, go to TipRanks’ Stock Analysis page.